Navigation Links
Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
Date:11/11/2010

llows:

"Bardoxolone methyl activates Keap1-Nrf2 and increases glutathione levels in cultured cells" by Ron Bumeister, Ph.D., Senior Scientist, Reata Pharmaceuticals

"Bardoxolone methyl improves markers of endothelial function in cultured cells" by Deborah A. Ferguson, Ph.D., Director, Discovery Biology, Reata Pharmaceuticals

"Treatment with Nrf2 activator ameliorates uremia-induced oxidative stress, endothelial dysfunction, and hypertension" by Stanislav Shelkovnikov, Ph.D., Associate Researcher, University of California, Irvine

"Treatment with an AIM increases GFR monitored by inulin clearance in rats" by W. Christian Wigley, Ph.D., Vice President, Research, Reata Pharmaceuticals

"Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria" by Carlamaria Zoja, Ph.D., Head, Laboratory of Experimental Models of Kidney Diseases, Mario Negri Institute for Pharmacological Research

"Effects of bardoxolone methyl on renal protein handling and secondary nephropathy" by Irina Dulubova, Ph.D., Director, Biochemistry and Structural Biology, Reata Pharmaceuticals

About Bardoxolone Methyl

Bardoxolone methyl is an antioxidant inflammation modulator (AIM) that activates Nrf2, thereby inducing the transcription of more than 250 genes that decrease the level of oxidative stress and suppress important inflammatory mediators.  In two Phase 2a studies, bardoxolone methyl was shown to produce a statistically significant increase in kidney function in patients with moderate to severe CKD and Type 2 diabetes.

About Chronic Kidney Disease and Diabetic Kidney Disease (Nephropathy)

CKD is a highly prevalent condition, affecting more than 50 million adults around the world.  Diabetes is the leading cause of CKD, with as many as 30 to 40 percent of Type 2 diabetics developing the disease.  Available therapies modestly slow the progression o
'/>"/>

SOURCE Reata Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
4. Arbor Pharmaceuticals Completes $34.8 Million Financing
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011
6. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
7. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. DUSA Pharmaceuticals to Present at the 4th Annual Maxim Group Growth Conference
10. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... WALTHAM, Mass. , March 22 Interleukin Genetics, Inc. (NYSE ... the NYSE Amex LLC (the "Exchange") has granted the Company an extension ... will remain listed up to June 23, 2010 , subject to ... towards the Company,s plan to regain compliance. , ...
... and Manufacturers of America (PhRMA) issued the following statement today on passage of comprehensive health care reform and accompanying reconciliation legislation in the U.S. House of Representatives: , ... , ... ... ...
Cached Medicine Technology:NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 2NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards 3PhRMA Statement on Health Care Reform 2PhRMA Statement on Health Care Reform 3PhRMA Statement on Health Care Reform 4PhRMA Statement on Health Care Reform 5
(Date:1/22/2015)... January 23, 2015 The U.S. Pharmacopeial ... DICVP, Director of Clinical Pharmacy Services at North Carolina ... recipient of the 2015 Beal Award for Distinguished Volunteer ... has relied on the contributions of volunteer experts to ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2
... adults on Medicare reports drinking more alcohol than is ... , Even though alcohol problems are more prevalent ... are consuming alcohol in amounts that exceed recommended guidelines, ... Universitys Heller School for Social Policy and Management. The ...
... Year Revenue Up 47.3% and Net Income Up 63.5% ... Company Declares Cash Dividend of US$0.18 ... Mindray,Medical International Limited (NYSE: MR ), a leading ... a rapidly growing,international presence, today announced its selected unaudited ...
... infertility risks, experts say , , WEDNESDAY, March 5 ... targeted treatment than standard chemotherapy, the effective and much-touted ... women still in their reproductive years, imatinib (Gleevec) might ... future, according to a case report published as a ...
... WALNUT CREEK, Calif., March 5 Longs Drug,Stores ... income from,continuing operations for the fourth quarter ended ... or $1.00 per diluted share, including a,$1.1 million ... of seven,California stores. Income from continuing operations for ...
... MED ) announced today that it will release fourth quarter ... 2007 on,Wednesday, March 12, 2008 after the market closes. The ... results on Thursday, March 13,2008 at 11:00 a.m. ET., ... or,(201) 689-8567, or can listen via a live Internet web ...
... 2008 The American Cancer Society, the American College ... on Colorectal Cancer (a group that comprises representatives ... Association, and American Society for Gastrointestinal Endoscopy) have ... cancer screening. The guidelines add two new tests ...
Cached Medicine News:Health News:New study sheds light on excessive drinking among the elderly 2Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 2Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 3Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 4Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 5Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 6Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 7Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 8Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 9Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 10Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 11Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 12Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 13Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 14Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 15Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 16Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 17Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 18Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 19Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 20Health News:Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results 21Health News:Gleevec May Disrupt Ovarian Function 2Health News:Gleevec May Disrupt Ovarian Function 3Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 2Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 3Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 4Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 5Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 6Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 7Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 8Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 9Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 10Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 11Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 12Health News:Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008 13
The anti-MAG autoantibodies EIA employs the quantitative enzymatically amplified sandwich-type immunoassay technique. HIGHLY PURIFIED MAG FROM HUMAN BRAIN has been precoated onto a microtiter plate....
... new Enzyme Immuno Assay (EIA) analyzer offering ... a dedicated EVO platform for reliable EIA ... and incubation units operated by the new ... available in three sizes - 100, 150, ...
... trial for 14 years -- and works! ... employs cutting-edge, patent-pending technology to attain the ... unsurpassed accuracy. The technique traces the amount ... blood to determine gender. Here's how it ...
Custom Pediatric Nebulizer Assembly W/Tubing...
Medicine Products: